CCL2 and arthritic joint disease: Another selective BTK inhibitor, CGI1746, has been reported to reduce CCL2 levels from macrophages in myeloid cell‐dependent arthritis by blocking trans‐phosphorylation of BTK Tyr551 and subsequent auto‐phosphorylation at Tyr223 (Di Paolo et al., 2011).